JPMorgan Calls the Selloff Excessive, Trims Regeneron Pharmaceuticals, Inc. (REGN) Price Target

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) after reducing its price objective from $950 to $800.

Why Regeneron Pharmaceuticals, Inc. (REGN) Crashed Last Week

A pharmacist in a lab coat carefully analyzing a vial of medicine for its quality.

Following poor IL-33 data in late May, the company believes that the recent selloff in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares is “very much overdone.”

JPMorgan pointed out that IL-33 was never a key component of its model, though. The company stressed that, even without accounting for any pipeline contribution, Dupixent, Eylea, and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’ solid cash position alone warrants a valuation far higher than current levels. JPMorgan anticipates several catalysts over the next six months that will help reset its value.

Recently, the firm’s valuation was under pressure due to its IL-33 program’s lackluster Phase results. JPMorgan is still optimistic in spite of this, concentrating on important assets like Dupixent and Eylea that support the company’s financial stability. The company’s updated $800 estimate, which reflects confidence in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s core business and future potential milestones, still suggests significant upside.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) discovers, develops, and commercializes drugs to treat eye disease, cardiovascular disease, cancer, and inflammation. It is one of the stocks with huge upside potential.

While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None.